NLNadine Loefflad

Nadine Loefflad

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nadine Loefflad has a total of 56 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Serum phosphorylated tau 217 in GBA1 variant carriers with and without Parkinson disease

    by Elisa Menozzi, Roxana Mezabrovschi, Aleesa Nazeer, Amelia Anderson, Nadine Loefflad, Amanda J Heslegrave, Elena Veleva, Vlada Drotsevitch, Matthew Gegg, Anthony Hv Schapira

    It is unclear whether Alzheimer disease pathology drives cognitive decline in Parkinson disease (PD) patients carrying GBA1 variants. We evaluated levels of serum phosphorylated tau 217 (p-tau217) in samples from 29 GBA1 -PD, 32 idiopathic PD, 20 non-manifesting GBA1 variant carriers ( GBA1 -NMC) and 31 healthy controls. No differences were detected between PD groups. GBA1 -NMCs showed higher levels than healthy controls, which correlated to worse cognition and subthreshold parkinsonism. Serum p-tau217 is not a marker of cognitive decline in GBA1 -PD. Whether p-tau217 levels in GBA1 -NMCs can predict conversion to PD or are a marker of cognitive decline, irrespective of PD, remains unknown.

  • Open Access

    Severe GBA1 variants drive the GBA1-PD clinical phenotype: implications for counselling and clinical trials

    by Elisa Menozzi, Sara Lucas Del Pozo, Jane Macnaughtan, Roxana Mezabrovschi, Sofia Koletsi, Pierfrancesco Mitrotti, Luca Gallo, Rosaria Calabrese, Marco Toffoli, Nadine Loefflad, et al.

    Variants in the GBA1 gene are the commonest genetic risk factor for Parkinson disease (PD). Genotype-phenotype correlations exist but with conflicting data. Here, we compared the clinical phenotype of 183 idiopathic PD (iPD) patients, 39 severe GBA1-PD, 24 mild GBA1-PD, and 55 risk GBA1-PD. Compared to iPD, we observed that only severe GBA1-PD patients had a distinctive, more several clinical profile, characterised by worse depression, hyposmia, cognitive dysfunction, and possibly constipation.


  • Open Access

    Microbiome signature of Parkinson disease in healthy and genetically at-risk individuals

    by Elisa Menozzi, Victoria Meslier, Yani Ren, Mallia Geiger, Jane Macnaughtan, Micol Avenali, Marine Gilles, Caterina Galandra, Pierfrancesco Mitrotti, Luca Gallo, et al.

    Summary: Parkinson disease (PD) is a major cause of disability with significant personal and system financial implications 1,2 . GBA1 variants are the commonest genetic risk factor for PD and increase the risk up to 30-fold 3,4 . Why only ∼20% of GBA1 variant carriers develop PD remains unknown. Here, by combining clinical and faecal metagenomics data from PD individuals carrying or not GBA1 variants, carriers of GBA1 variants not manifesting PD symptoms (GBA-NMC) and healthy controls, and using an innovative microbiome analysis, we show that a large component of the gut microbiome evolves from healthy across GBA-NMC towards PD and is strongly correlated with disease progression in patients, and prodromal symptoms suggestive of future development of PD in GBA-NMC. By using species altered in PD and GBA-NMC, we detect healthy individuals with the strongest prodromal PD clinical profile. These findings indicate that gut microbiome alterations can identify individuals with GBA1 variants most prone to develop PD and individuals in the general population that may be progressing towards PD. Healthy nutrition mitigates microbiome alterations associated with disease severity, suggesting that it could modify disease progression in PD patients and decrease the risk of disease development in healthy individuals including those with GBA1 variants.


  • Open Access

    Phenotypic effect of GBA1 variants in individuals with and without Parkinson disease: the RAPSODI study

    by M Toffoli, H Chohan, S Mullin, A Jesuthasan, S Yalkic, S Koletsi, E Menozzi, S Rahall, N Limbachiya, N Loefflad, et al.

    Background: Variants in the GBA1 gene cause the lysosomal storage disorder Gaucher disease (GD). They are also risk factors for Parkinson disease (PD), and modify the expression of the PD phenotype. The penetrance of GBA1 variants in PD is incomplete, and the ability to determine who amongst GBA1 variant carriers are at higher risk of developing PD, would represent an advantage for prognostic and trial design purposes. Objectives: To compare the motor and non-motor phenotype of GBA1 carriers and non-carriers. Methods: We present the cross-sectional results of the baseline assessment from the RAPSODI study, an online assessment tool for PD patients and GBA1 variant carriers. The assessment includes clinically validated questionnaires, a tap-test, the University of Pennsyllvania Smell Identification Test and cognitive tests. Additional, homogeneous data from the PREDICT-PD cohort were included. Results: A total of 379 participants completed all parts of the RAPSODI assessment (89 GBA1 -negative controls, 169 GBA1 -negative PD, 47 GBA1 -positive PD, 47 non-affected GBA1 carriers, 27 GD). Eightysix participants were were recruited through PREDICT-PD (43 non-affected GBA1 carriers and 43 GBA1 -negative controls). GBA1 -positive PD showed worse performance in visual cognitive tasks and olfaction compared to GBA1 -negative PD patients. No differences were detected between non-affected GBA1 carriers carriers and GBA1 -negative controls. No phenotypic differences were observed between any of the non-PD groups. Conclusions: Our results support previous evidence that GBA1 -positive PD has a specific phenotype with more severe non-motor symptoms. However, we did not reproduce previous findings of more frequent prodromal PD signs in non-affected GBA1 carriers.